JO3115B1 - مركبات بيريدازينون واستخدامها كمثبطات daao - Google Patents

مركبات بيريدازينون واستخدامها كمثبطات daao

Info

Publication number
JO3115B1
JO3115B1 JOP/2012/0232A JOP20120232A JO3115B1 JO 3115 B1 JO3115 B1 JO 3115B1 JO P20120232 A JOP20120232 A JO P20120232A JO 3115 B1 JO3115 B1 JO 3115B1
Authority
JO
Jordan
Prior art keywords
pyridazinone compounds
daao inhibitors
daao
inhibitors
compounds
Prior art date
Application number
JOP/2012/0232A
Other languages
English (en)
Inventor
Livermore David
Miller David
Fieldhouse Charlotte
Kerr Catrina
Hazel Katherine
Merchant Kevin
Kinsella Natasha
Farnaby William
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1114399.7A external-priority patent/GB201114399D0/en
Priority claimed from GB201118658A external-priority patent/GB201118658D0/en
Priority claimed from GBGB1203533.3A external-priority patent/GB201203533D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3115B1 publication Critical patent/JO3115B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوفر الاختراع الحالى مركبات الصيغة (I) وأملاحها المقبولة صيدلياً، (I) حيث R1 وR2 تكون كما هى معرفة فى الوصف، عمليات لتحضيرها، تركيبات صيدلية تحتوى عليها واستخدامها فى العلاج.
JOP/2012/0232A 2011-08-22 2012-08-15 مركبات بيريدازينون واستخدامها كمثبطات daao JO3115B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1114399.7A GB201114399D0 (en) 2011-08-22 2011-08-22 Novel compounds
GB201118658A GB201118658D0 (en) 2011-10-27 2011-10-27 Novel compounds
GBGB1203533.3A GB201203533D0 (en) 2012-02-29 2012-02-29 Novel compounds

Publications (1)

Publication Number Publication Date
JO3115B1 true JO3115B1 (ar) 2017-09-20

Family

ID=46758786

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0232A JO3115B1 (ar) 2011-08-22 2012-08-15 مركبات بيريدازينون واستخدامها كمثبطات daao

Country Status (38)

Country Link
US (6) US9290456B2 (ar)
EP (1) EP2748149B9 (ar)
JP (1) JP6022573B2 (ar)
KR (1) KR101961851B1 (ar)
CN (1) CN103748079B (ar)
AP (1) AP2014007512A0 (ar)
AR (2) AR087607A1 (ar)
AU (1) AU2012298335B2 (ar)
BR (1) BR112014003906B1 (ar)
CA (1) CA2846204C (ar)
CL (1) CL2014000395A1 (ar)
CO (1) CO6910197A2 (ar)
CR (1) CR20140133A (ar)
CY (1) CY1117105T1 (ar)
DK (1) DK2748149T5 (ar)
DO (1) DOP2014000036A (ar)
EA (1) EA024956B1 (ar)
EC (1) ECSP14013215A (ar)
ES (1) ES2559631T3 (ar)
GE (1) GEP20156372B (ar)
HK (1) HK1194072A1 (ar)
HR (1) HRP20151310T2 (ar)
HU (1) HUE026691T2 (ar)
IL (1) IL230143A (ar)
JO (1) JO3115B1 (ar)
ME (1) ME02319B (ar)
MX (1) MX2014000783A (ar)
MY (1) MY180618A (ar)
PE (1) PE20141208A1 (ar)
PL (1) PL2748149T3 (ar)
PT (1) PT2748149E (ar)
RS (1) RS54515B9 (ar)
SI (1) SI2748149T1 (ar)
SM (1) SMT201600023B (ar)
TW (1) TWI546289B (ar)
UY (1) UY34280A (ar)
WO (1) WO2013027000A1 (ar)
ZA (1) ZA201400153B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EA032088B1 (ru) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
PE20141361A1 (es) * 2011-11-15 2014-10-13 Takeda Pharmaceutical Compuesto heterociclico dihidroxi aromatico
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9956113B2 (en) 2013-03-12 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Method and system for regulating core body temperature
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
CN112773798B (zh) * 2014-04-30 2024-03-29 宇凤·简·曾 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
EP3310764B1 (en) 2015-06-19 2023-04-19 Massachusetts Institute of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
WO2022187127A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636632A5 (de) 1976-10-08 1983-06-15 Ciba Geigy Ag Neues verfahren zur herstellung von schwermetallkomplexen.
LU75958A1 (ar) 1976-10-08 1978-05-16
GB2025416A (en) 1978-07-14 1980-01-23 Pfizer Ltd Mercaptopyridazinethione antifungal agents
GB8421427D0 (en) 1984-08-23 1984-09-26 Smith Kline French Lab Chemical compounds
EG18314A (en) 1985-09-26 1993-02-28 Squibb & Sons Inc Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines
US4743685A (en) 1985-09-26 1988-05-10 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
DK170088A (da) 1987-04-10 1988-10-11 Hoffmann La Roche Acylderivater
WO1989000423A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
JPH01202875A (ja) 1988-02-09 1989-08-15 Fujitsu Ltd 超伝導材料構造の製造方法
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DK0489515T3 (da) 1990-11-22 1995-11-06 Cerestar Holding Bv Fremgangsmåde til fremstilling af chokolade
EP0544166A3 (en) 1991-11-26 1993-11-03 Hoffmann La Roche Cephalosporinderivatives
GB9219313D0 (en) 1992-09-11 1992-10-28 Kodak Ltd Method of forming a photographic colour image
WO1995011235A1 (en) 1993-10-20 1995-04-27 The Upjohn Company Pyrimidinones as antiarthritic and anti-inflammatories
CA2196995C (en) 1994-08-24 2008-05-13 Michael Balestra Spiro-azabicyclic compounds useful in therapy
JPH092534A (ja) 1995-06-16 1997-01-07 Terada Seisakusho:Kk 茶貯蔵容器
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
BR9812127A (pt) 1997-08-22 2000-07-18 Abbott Lab Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
KR100666838B1 (ko) 1998-10-27 2007-01-11 아보트 러보러터리즈 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제 및 이를 포함하는 약제학적 조성물
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2002028187A (ja) 2000-07-14 2002-01-29 Toto Ltd 車いす
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
CN101486683B (zh) * 2000-09-18 2011-12-21 卫材R&D管理有限公司 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
JP4549024B2 (ja) 2001-05-18 2010-09-22 アストラゼネカ・アクチエボラーグ ４（フェニル−ピペラジニル−メチル）ベンズアミド誘導体及び疼痛、不安症又は胃腸障害の治療のためのその使用
NZ529426A (en) 2001-06-01 2005-07-29 Astrazeneca Ab Spiroazabicyclic heterocyclic amine ligands for nicotinic acetylcholine receptors useful in therapy
WO2003047558A2 (en) 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
KR20040099446A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 헤테로시클릭 화합물
NZ561794A (en) 2002-04-18 2008-11-28 Astrazeneca Ab Furyl spiroazabicyclic heterocyclic amines as nicotinic acetylcholine agonists
AU2003224545B2 (en) 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
BRPI0409649A (pt) 2003-04-23 2006-04-25 Pharmacia & Upjohn Co Llc pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
PL380887A1 (pl) 2003-12-29 2007-04-02 Sepracor Inc. Pirolowe i pirazolowe inhibitory DAAO
US7915424B2 (en) 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
AU2006257863A1 (en) 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
TWI375669B (en) 2006-03-17 2012-11-01 Sumitomo Chemical Co Pyridazinone compound and use thereof
WO2008005456A2 (en) * 2006-06-30 2008-01-10 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2008089453A2 (en) 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of d-amino acid oxidase
AR064962A1 (es) 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
JP5147866B2 (ja) * 2007-03-15 2013-02-20 メルク・シャープ・アンド・ドーム・コーポレーション グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
MX2009010407A (es) 2007-03-28 2009-12-01 Apotex Technologies Inc Derivados fluorados de deferiprona.
WO2008156607A1 (en) * 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
JP2009002534A (ja) 2007-06-19 2009-01-08 Denso Corp 熱交換器
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010017418A1 (en) 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010058314A1 (en) * 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
HUE027478T2 (en) 2009-02-05 2016-09-28 Takeda Pharmaceuticals Co Pyridazinone Compounds
US20130065857A1 (en) 2009-10-12 2013-03-14 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
BR112012021656A2 (pt) 2010-03-04 2017-02-07 Merck Sharp & Dohme composto, uso do mesmo, e, composição farmacêutica
EP2542076B1 (en) 2010-03-04 2021-01-13 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
MX2012010188A (es) 2010-03-04 2012-10-03 Merck Sharp & Dohme Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
US20120046232A1 (en) 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
AU2012275499A1 (en) 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
PE20141361A1 (es) 2011-11-15 2014-10-13 Takeda Pharmaceutical Compuesto heterociclico dihidroxi aromatico
US8868710B2 (en) 2011-11-18 2014-10-21 Amazon Technologies, Inc. Virtual network interface objects
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds

Also Published As

Publication number Publication date
US20130052281A1 (en) 2013-02-28
ME02319B (me) 2016-06-20
WO2013027000A1 (en) 2013-02-28
SMT201600023B (it) 2016-02-25
DK2748149T3 (en) 2016-01-25
CA2846204C (en) 2021-04-27
SI2748149T1 (sl) 2016-02-29
KR101961851B1 (ko) 2019-03-26
JP2014524461A (ja) 2014-09-22
ECSP14013215A (es) 2014-05-31
US20180177780A1 (en) 2018-06-28
KR20140054297A (ko) 2014-05-08
NZ620239A (en) 2015-10-30
EP2748149B9 (en) 2017-11-15
MY180618A (en) 2020-12-03
CY1117105T1 (el) 2017-04-05
US20150030704A1 (en) 2015-01-29
JP6022573B2 (ja) 2016-11-09
US20220008416A1 (en) 2022-01-13
ZA201400153B (en) 2015-12-23
US20170173007A1 (en) 2017-06-22
IL230143A (en) 2017-03-30
MX2014000783A (es) 2014-04-14
TWI546289B (zh) 2016-08-21
CO6910197A2 (es) 2014-03-31
CN103748079B (zh) 2016-03-16
EA201490471A1 (ru) 2014-05-30
CA2846204A1 (en) 2013-02-28
GEP20156372B (en) 2015-09-25
HUE026691T2 (hu) 2016-07-28
US9290456B2 (en) 2016-03-22
AU2012298335B2 (en) 2017-06-01
US11129828B2 (en) 2021-09-28
US10463663B2 (en) 2019-11-05
US9931340B2 (en) 2018-04-03
TW201313687A (zh) 2013-04-01
EP2748149A1 (en) 2014-07-02
EP2748149B1 (en) 2015-10-21
BR112014003906A2 (pt) 2017-03-14
EA024956B1 (ru) 2016-11-30
AU2012298335A1 (en) 2014-01-30
AP2014007512A0 (en) 2014-03-31
HRP20151310T2 (hr) 2018-03-23
AR087607A1 (es) 2014-04-03
HK1194072A1 (en) 2014-10-10
DOP2014000036A (es) 2014-06-30
DK2748149T5 (en) 2017-04-24
UY34280A (es) 2012-10-31
BR112014003906B1 (pt) 2022-03-22
CN103748079A (zh) 2014-04-23
CL2014000395A1 (es) 2014-12-05
CR20140133A (es) 2014-06-05
IL230143A0 (en) 2014-03-06
ES2559631T3 (es) 2016-02-15
US20200121678A1 (en) 2020-04-23
PE20141208A1 (es) 2014-09-19
AR127309A2 (es) 2024-01-10
PT2748149E (pt) 2016-02-04
RS54515B1 (en) 2016-06-30
RS54515B9 (sr) 2020-12-31
HRP20151310T1 (en) 2016-01-01
PL2748149T3 (pl) 2016-04-29
ES2559631T9 (es) 2018-03-13

Similar Documents

Publication Publication Date Title
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12017502141A1 (en) Compounds and their methods of use
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
IN2014MN02598A (ar)
PH12015500260A1 (en) Neprilysin inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
IN2014CN04530A (ar)
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2014001004A (es) Indazoles.
MX2014012695A (es) Derivados de isoindolona.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY175854A (en) Novel quinolone derivatives
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2013004995A8 (en) Pyrimidinone compounds and their use
IN2015DN01119A (ar)
MX340300B (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
GB201209587D0 (en) Therapeutic compounds
TW201613864A (en) Novel compounds
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX340574B (es) Imidazo pirazinas.
MX362879B (es) Usos novedosos.
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors